Anti-Poly(ethylene glycol) (PEG) Antibodies: From Where Are We Coming and Where Are We Going

PEGylation technology confers stability and modulates the biological performance of a broad range of preclinical and clinical nanopharmaceuticals. However, the emerging PEG immunogenicity in the general population is thought to impact the efficacy and safety of PEGylated medicines. Despite this, the...

Full description

Saved in:
Bibliographic Details
Published inJournal of nanotheranostics Vol. 5; no. 3; pp. 99 - 103
Main Authors Simberg, Dmitri, Moghimi, S. Moein
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 29.07.2024
Subjects
Anaphylaxis
Antibodies
Clinical significance
complement system
COVID-19 vaccines
Immunogenicity
Leukocytes
Lipids
Nanoparticles
Neutrophils
Pharmaceuticals
poly(ethylene glycol)
Polyethylene glycol
Proteins
Severe acute respiratory syndrome coronavirus 2
Toxicity
Online AccessGet full text

Cover

More Information
Summary:PEGylation technology confers stability and modulates the biological performance of a broad range of preclinical and clinical nanopharmaceuticals. However, the emerging PEG immunogenicity in the general population is thought to impact the efficacy and safety of PEGylated medicines. Despite this, the clinical significance of PEG immunogenicity is still not clear and remains debatable. By considering the strategic importance of the PEGylation technology in nanopharmaceutical engineering, we raise a number of critical questions and briefly discuss gaps in the knowledge of PEG immunogenicity and its clinical significance.
ISSN:2624-845X
2624-845X
DOI:10.3390/jnt5030007